AUTOLOGOUS AML PLATFORM

Autologous Acute Myeloid Leukemia (AML) Platform

Historically, AML is a heterogeneous and complex disease, therefore, the road to an effective treatment has been challenging. However, new innovative treatments including improved chemotherapies, mutationally targeted inhibitors, pro-apoptotic agents, microenvironment targeting molecules, cell cycle checkpoint inhibitors, epigenetic regulators and more recently, immuno-oncology agents are being developed to treat AML patients. These new therapeutics, such as monoclonal antibodies, bi-specific antibodies or antibody-drug conjugates need to be tested in various platforms prior to reaching the clinic. Champions Oncology has launched an innovative new platform enabling AML researchers the ability to better understand their therapeutic mechanism of action. The Autologous AML Platform is an ex vivo co-culture assay developed and optimized to interrogate the responses of your immuno-oncology drugs in only 4 days using primary patient specimens.

Champions' Extensive AML Bank Available for Therapeutic Testing

Champion's AML bank contains patient samples that are never passaged to retain clinical relevance. Currently the bank contains 38 AML models, several with commonly observed mutations, listed below.

AML Model Classes



AML Pathogenic Mutations

Gene/Alteration	# mutant models	# wild type models
IDH1/2	3	17
FLT3 ITD	14	10
NPM1	9	13
CUX1	17	N/A
RUNX1	7	N/A
KIT	11	N/A
DNMT3A	14	N/A
STAG2	16	N/A
TP53	14	N/A

AML Patient Diagnoses



Autologous Hematological Assay

The Autologous AML Platform utilizes a short-term culture system that supports the growth and survival of primary AML and patient matched T Cells ex vivo with the addition of cytokine supplemented media for 4 days.



CHAMPIONS ONCOLOGY

www.ChampionsOncology.com

All Rights Reserved 2022

Corporate Headquarters
One University Plaza, Suite 307
Hackensack, NJ 07601

Optimized Flow Cytometry Standard AML Immunophenotyping Panel





Markers
hCD3
hCD4
hCD8
hCD25
hCD33
hCD45
hCD69
hCD123
Viability Dye

Three Open Channels for Client Choice

Standard AML Immunophenotyping Panel Gating Strategy



AML Cells Survive and T Cells Expand in Culture

Cells were plated either unstimulated or with αCD3/αCD28 to stimulate T Cell expansion. The 3 representative primary AML models shown below have a healthy AML cell population (CD3- CD33+) in the unstimulated wells after 8-10 days of co-culture and the T Cells (CD3+ CD33-) show significant expansion after stimulation with αCD3/αCD28.



T Cells Express Activation Markers in Culture

In addition to T Cell expansion, the αCD3/αCD28 stimulated cells also express increased levels of CD25 and CD69, which are known markers of T Cell activation, shown below in 2 representative primary AML models. Therefore, the co-cultured T Cells have the ability to proliferate and be activated by a stimulant.



Access Champions Model Select® database for updated information about Champions' PDX Models.

www.ChampionsOncology.com

© 2022 All Rights Reserved

Corporate Headquarters
One University Plaza, Suite 307
Hackensack, NJ 07601